<DOC>
	<DOCNO>NCT01182272</DOCNO>
	<brief_summary>RATIONALE : Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sorafenib tosylate work treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Sorafenib Tosylate Treating Patients With Liver Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess anti-tumor activity neoadjuvant sorafenib tosylate tumor sample patient resectable hepatocellular carcinoma ( HCC ) . Secondary - To characterize pathologic finding sorafenib tosylate pre-treated patient undergo surgical resection HCC : 1-2 core tumor biopsy perform prior treatment day 35 . - To evaluate number R0 resection patient . - To correlate pathological biomarker change resect tumor 4-week treatment sorafenib tosylate comparison biopsy obtain prior treatment patient . - To evaluate plasma biomarkers , include PIGF , VEGF-A , VEGF-C , sVEGFR2 , sVEGFR3 , sKIT , IL-6 , Ang2 , IL-8 , bFGF , AFP , collagen 4 , endostatin , thrombospondin , TSP-1 angiostatin , CXCL12 baseline , day 28 , day surgery . - To identify potential biomarkers sensitivity and/or resistance biological pathological sample patient ( exploratory ) . - To characterize safety profile sorafenib tosylate patient . - To assess tolerance liver resection sorafenib tosylate treatment patient . OUTLINE : This multicenter study . Patients receive oral sorafenib tosylate twice daily day 1-28 absence unacceptable toxicity . Approximately 7 day completion sorafenib tosylate therapy , patient undergo liver resection . Blood tissue specimen collect periodically laboratory biomarker assessment . Biomarkers include molecular marker investigate direct antitumor effect sorafenib tosylate cancer cell vs effect drug angiogenesis . After completion study treatment , patient follow day 50 3 month surgery .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hepatocellular carcinoma ( HCC ) Fibrolamellar mixed histology allow No cholangiocarcinoma tubal disease Must eligible conservative hepatic resection liver resection curative intent No cirrhosis ChildPugh score &gt; 7 Chronic liver disease without liver insufficiency without portal liver hypertension allow No known history presence metastatic brain meningeal tumor PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 3 month WBC &gt; 3,000/µL ANC &gt; 1,500/µL Platelet count ≥ 100,000/µL Hemoglobin ≥ 9 g/dL Bilirubin &lt; 1.5 time upper normal limit ( ULN ) AST ALT ≤ 5 time UNL Alkaline phosphatase ≤ 5 time ULN Serum creatinine &lt; 2 time ULN PT/INR/PTT &lt; 1.5 time UNL Amylase lipase &lt; 1.5 time ULN Negative pregnancy test Fertile patient must use effective contraception Body mass index 18.530 kg/m^2 ( WHO normal range : 18.525 kg/m^2 ) Able swallow oral compound No criterion unresectability medical condition contraindicates surgical resection No serious concurrent systemic disorder incompatible study , include follow : Uncontrolled hypertension ( i.e. , BP &gt; 150/100 mm Hg despite optimal therapy ) Active uncontrolled infection Active alcoholism No prior medical disorder , include follow : Cardiac arrhythmia require antiarrhythmic ( exclude betablockers digoxin chronic atrial fibrillation ) Active coronary artery disease ischemia Myocardial infarction within past 6 month NYHA class IIIIV congestive heart failure Pulmonary embolism within past 6 month Gastrointestinal bleeding within past 6 month No prior malignancy within past 5 year , except basal cell squamous cell skin carcinoma cure situ cervical carcinoma No history concurrent seizure disorder require medication ( e.g. , antiepileptic drug ) No history HIV infection , chronic hepatitis B C No active clinically serious bacterial fungal infection ( i.e. , grade 2 CTCAE v. 3 ) No condition unstable could jeopardize safety patient his/her compliance study No substance abuse medical , psychological , social condition could interfere adherence study No known suspect allergy investigational agent agent give concurrently No presence asthenia rash &gt; CTC grade 1 enrollment Must register national healthcare system PRIOR CONCURRENT THERAPY : No prior orthotopic liver transplantation Not candidate orthotopic liver transplantation No prior systemic locoregional treatment HCC No prior organ allograft No treatment investigational medicinal product within past 28 day No concurrent treatment fulldose anticoagulant Deepvein catheterassociated thrombosis prophylaxis allow Warfarin heparin therapy allow coagulation parameter within acceptable range prior initiation anticoagulant therapy No concurrent chronic coadministration CYP3A4 inducer ( e.g. , rifampin , Hypericum perforatum , phenytoin , carbamazepine , phenobarbital , dexamethasone )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize resectable adult primary liver cancer</keyword>
</DOC>